Wilf Family Cardiovascular Research Institute, Department of Medicine (Cardiology), Albert Einstein College of Medicine, New York, New York, USA.
Address correspondence to: Nikolaos G. Frangogiannis, The Wilf Family Cardiovascular Research Institute, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Forchheimer G46B, Bronx, New York 10461, USA. Phone: 718.430.3546; E-mail: email@example.com.
Published May 1, 2017 - More info
The cardiac extracellular matrix (ECM) not only provides mechanical support, but also transduces essential molecular signals in health and disease. Following myocardial infarction, dynamic ECM changes drive inflammation and repair. Early generation of bioactive matrix fragments activates proinflammatory signaling. The formation of a highly plastic provisional matrix facilitates leukocyte infiltration and activates infarct myofibroblasts. Deposition of matricellular proteins modulates growth factor signaling and contributes to the spatial and temporal regulation of the reparative response. Mechanical stress due to pressure and volume overload and metabolic dysfunction also induce profound changes in ECM composition that contribute to the pathogenesis of heart failure. This manuscript reviews the role of the ECM in cardiac repair and remodeling and discusses matrix-based therapies that may attenuate remodeling while promoting repair and regeneration.
The mammalian myocardium comprises cardiomyocytes and large populations of interstitial noncardiomyocytes (1) enmeshed within an intricate network of extracellular matrix (ECM) proteins. In health, the cardiac ECM does not simply serve as a mechanical scaffold, but may also transduce signals that are important for cell survival and function. Most cardiac pathologic conditions are associated with expansion of the cardiac interstitial matrix and with marked alterations in its composition (2, 3); these changes perturb cardiac systolic and diastolic function. In myocardial infarction, sudden death of up to a billion cardiomyocytes overwhelms the extremely limited regenerative capacity of the adult mammalian heart. As a result, the infarcted ventricle heals through activation of a superbly orchestrated cellular response that clears the wound of dead cells and matrix debris, ultimately leading to formation of a collagen-based scar (4). In conditions associated with pressure or volume overload, dynamic alterations in the ECM network may affect cardiomyocyte survival and may regulate the response of interstitial cells to mechanical stress. Metabolic diseases are also associated with profound alterations in the composition of the cardiac ECM that contribute to the pathogenesis of diastolic dysfunction and may suppress the myocardial reparative reserve. Despite increased recognition of its role in mediating cell biological responses, the contribution of the ECM in cardiac pathophysiology remains underappreciated. This Review discusses the dynamic alterations of the ECM following cardiac injury and their contribution to cardiac remodeling and function.
The myocardial matrix network comprises primarily fibrillary collagen that is organized on three interconnected levels: the endomysium surrounds individual cardiomyocytes, the perimysium defines major bundles, and the epimysium encases the entire cardiac muscle (5, 6). In all mammalian species studied to date, type I collagen is the major structural component of the cardiac interstitium, accounting for approximately 85% to 90% of the collagenous matrix (7), and is predominantly localized in the epimysium and perimysium. In contrast, type III collagen represents 5% to 11% of total myocardial collagen and is more prominent in the endomysium (7–9). In addition to collagens, the cardiac ECM also contains fibronectin, glycosaminoglycans, and proteoglycans, and it serves as a reservoir for growth factors and proteases, which are stored in the normal matrix and can be activated following injury. Although the role of the matrix network in providing structural support, preserving ventricular geometry, and facilitating force transmission is intuitive, the collagen-based cardiac matrix also transduces key signals necessary for survival and function of both cardiomyocytes and noncardiomyocytes. The molecular pathways responsible for the interactions between matrix proteins and the cellular elements in normal hearts remain poorly understood.
Repair of the infarcted myocardium can be divided into three distinct but overlapping phases: the inflammatory phase, the proliferative phase, and the maturation phase (10). In all three phases of infarct healing, the dynamic changes in the composition of the ECM play a critical role in regulation of the cellular responses that mediate cardiac repair (11). During the inflammatory phase, early degradation of matrix proteins generates bioactive fragments (termed matrikines) that may contribute to activation of inflammatory and reparative cascades (Figure 1). Moreover, formation of a provisional matrix network derived from extravasated plasma proteins serves as a highly plastic conduit for infiltrating inflammatory cells. Removal of dead cells and matrix debris by professional phagocytes induces release of antiinflammatory mediators, marking the transition to the proliferative phase of cardiac repair. At this stage, the ECM is enriched through induction and deposition of matricellular proteins, defined as extracellular macromolecules that do not serve a primary structural role, but modulate cellular phenotype, activate proteases and growth factors, and transduce signaling cascades (12, 13). Activated myofibroblasts are the dominant cells during the proliferative phase of cardiac repair and deposit large amounts of structural ECM proteins. Finally, during the maturation phase, crosslinking of the ECM, fibroblast quiescence, and vascular maturation lead to formation of a stable collagen-based scar.
The ECM during the inflammatory phase of cardiac repair. (A) Cardiomyocyte necrosis is associated with induction and activation of proteases in the infarcted region. Activated proteases cause fragmentation of the native ECM, resulting in release of matrikines, bioactive peptides that activate an inflammatory macrophage phenotype and may also modulate responses of fibroblasts and vascular endothelial cells. The effects of MMPs in the ischemic and infarcted myocardium are not limited to the ECM. MMPs may modulate inflammatory and reparative responses by processing cytokines and chemokines. They may also inhibit chemokine actions by degrading glycosaminoglycan-binding sites and mediate dysfunction by targeting intracellular proteins. Increased vessel permeability in the infarcted region results in extravasation of plasma proteins, such as fibrinogen and fibronectin. Accumulation of these proteins in the infarcted region forms a provisional matrix that serves as a scaffold for infiltrating leukocytes. Fibrin and fibronectin modulate the phenotype of immune and reparative cells through integrin-mediated actions. (B) Fibrinogen/fibrin staining using a peroxidase-based technique (black) illustrates the formation of the provisional fibrin-based matrix network (indicated by arrows) in the infarcted canine myocardium (one hour ischemia followed by seven days reperfusion). Counterstained with eosin. Scale bar: 50 μm. Reproduced with permission from the FASEB Journal (155).
Activation of matrix metalloproteinases. Myocardial ischemia causes rapid activation of latent matrix metalloproteinases (MMPs) and subsequent generation of matrix fragments (14, 15). MMP activation is detected in the cardiac interstitium as early as ten minutes after coronary occlusion (16), before any evidence of irreversible cardiomyocyte injury, and may be driven by ischemia-mediated ROS generation (17). Cardiomyocyte necrosis accentuates the matrix-degrading response. Large amounts of MMPs are synthesized de novo by ischemic cardiomyocytes, fibroblasts, endothelial cells, and inflammatory leukocytes that infiltrate the infarct (18). Both collagenases (e.g., MMP1) and gelatinases (MMP2 and MMP9) are upregulated in the infarcted myocardium (19).
It should be emphasized that the actions of MMPs are not limited to effects on the ECM. MMPs regulate inflammatory responses through proteolytic processing of cytokines, chemokines, and growth factors (20–24) or by degrading glycosaminoglycan binding sites, thus interfering with a molecular step that is critical for chemokine immobilization on the endothelial cell surface and subsequent interaction with leukocytes (25). MMPs also have intracellular targets, degrading cardiomyocyte proteins, such as myosin, α-actinin, and titin (26–28). The relative significance of the matrix-independent actions of MMPs in the pathogenesis of ischemic dysfunction and postinfarction remodeling remains unknown.
Generation of matrikines. In injured and remodeling tissues, protease-mediated fragmentation of matrix proteins results in generation of matrikines (29–32). Elastin fragments and collagen-derived peptides are the best-studied matrikines and have been implicated in activation of immune cells and fibroblasts (29, 33). The collagen-derived tripeptide proline-glycine-proline (PGP) and its acetylated form have been demonstrated as acting as neutrophil chemoattractants in models of pulmonary inflammation, signaling through activation of the chemokine receptor CXCR2 (34). PGP generation requires activation of a multistep cascade that involves MMP8, MMP9, and prolyl endopeptidase (35). Proteolytic processing of laminins by MMP2 and MMP14 has also been demonstrated as yielding fragments with potent neutrophil chemoattractant properties (36).
Although the rapid activation of MMPs in the infarct is associated with matrix fragmentation, the role of these fragments as bioactive proinflammatory matrikines has not been documented. In experimental models, release of type I collagen fragments in the serum has been documented within 30 minutes after coronary occlusion (37). Fragmentation of components of the basement membrane, such as collagen IV, and of noncollagenous matrix constituents has also been demonstrated in the infarcted myocardium (38–41). Low–molecular weight hyaluronan fragments exert potent proinflammatory actions in the infarcted region; impaired clearance of these fragments has been shown to prolong and accentuate proinflammatory signaling in leukocytes and vascular cells (42, 43). Matrix fragments may also modulate fibroblast and vascular cell phenotype (44). Endostatin, a 20-kDa fragment of collagen XVIII, exerts potent angiostatic actions (45) and stimulates fibroblast proliferation (46). MMP9-mediated cleavage of collagen IV also generates fragments with angiostatic properties, such as tumstatin (47). The role of endogenous matrix fragments in regulation of fibrogenic and angiogenic responses following myocardial infarction remains poorly understood.
The plasma-derived provisional matrix regulates the inflammatory response. Degradation of the original cardiac matrix network in the infarcted myocardium is accompanied by formation of a provisional matrix (39). Rapid induction of VEGF in the infarcted heart increases vascular permeability (48), leading to extravasation of plasma fibrinogen and fibronectin and generating a complex and dynamic fibrin-based matrix network (39, 49). The role of the provisional matrix in regulating cardiac repair remains poorly understood; current concepts are predominantly based on extrapolation of findings from studies that investigate reparative responses in other systems. In addition to its hemostatic role, the provisional matrix may serve as a scaffold for migrating inflammatory cells and support proliferating endothelial cells and fibroblasts (50). Components of the provisional matrix interact with migrating cells through cell surface integrins (51) and may also transduce signaling cascades that modulate immune cell phenotype and gene expression (52). In vitro, fibrinogen stimulates macrophage-derived chemokine secretion through TLR4 activation (53).
In a mouse model of reperfused myocardial infarction, fibrin-mediated interactions contributed to early injury by accentuating the inflammatory response (54). Treatment with a naturally occurring peptide that competes with the fibrin fragment N-terminal disulfide knot-II (an analog of the fibrin E1 fragment) for binding to vascular endothelial cadherin reduced infarct size, attenuating leukocyte infiltration in the ischemic myocardium in both rodent and large animal models (54, 55). Unfortunately, the effects of the peptide in a small clinical trial were much less impressive. Peptide administration in patients with ST-elevation myocardial infarction (STEMI) did not affect the size of the infarct assessed through magnetic resonance imaging and did not reduce serum troponin I levels (56).
The provisional matrix may also play an important role in the transition to the proliferative phase of cardiac repair by serving as a reservoir for cytokines and growth factors. The heparin-binding domain of fibrin binds to a wide range of growth factors, including members of the PDGF, FGF, VEGF, and TGF families (57), that may activate reparative fibroblasts and vascular cells.
Dynamic changes in the composition of the ECM may contribute to the reparative cellular responses during the proliferative phase of cardiac repair (Figure 2). Clearance of matrix fragments by phagocytes may activate antiinflammatory signals, suppressing recruitment of proinflammatory leukocytes. Lysis of the plasma-derived provisional matrix is followed by organization of a cell-derived matrix network, comprising cellular fibronectin, hyaluronan, proteoglycans, and a wide range of matricellular macromolecules (39) that transduce growth factor signals to reparative cells (58). The dynamic alterations of the ECM during the proliferative phase provide essential signals for conversion of fibroblasts into myofibroblasts and may activate angiogenic pathways necessary for neovessel formation, thus supplying the metabolically active wound with oxygen and nutrients (11).
The role of the cell-derived provisional matrix in cardiac repair. (A) During the proliferative phase of cardiac repair, fibroblasts and macrophages contribute to the formation of a cell-derived provisional matrix, enriched with a wide range of matricellular macromolecules that do not serve a primary structural role, but modulate cellular phenotype and function. Specialized matrix proteins (such as ED-A domain fibronectin) and matricellular proteins, such as TSPs, tenascin-C (TNC), osteopontin (OPN), SPARC, periostin, osteoglycin, and members of the CCN family, bind to the matrix and modulate growth factor and protease activity. Specific matricellular proteins have been reported as regulating inflammation, participating in fibrogenic and angiogenic responses, modulating cardiomyocyte survival, and contributing to assembly of the structural matrix. (B) Matricellular proteins may be critical in spatial and temporal regulation of growth factor signaling. Immunohistochemical staining using a peroxidase-based technique (black) shows the strikingly selective localization of the prototypical matricellular protein TSP1 (arrows), a critical activator of TGF-β, in the border zone of a healing canine myocardial infarction (one hour ischemia followed by seven days reperfusion). Spatially and temporally restricted induction of matricellular proteins regulates growth factor signaling, preventing expansion of profibrotic responses beyond the infarcted area, despite possible diffusion of the soluble mediators in viable segments. Counterstained with eosin. Reproduced with permission from Circulation (75). Scale bar: 50 μm. GAGs, glycosaminoglycosans.
Fibrin network clearance and cell-derived provisional matrix formation. In healing wounds, the plasma-derived ECM is cleared through extracellular proteolysis by fibrinolytic enzymes (59) and through endocytosis by CCR2+ macrophages (60). In the healing infarct, clearance of the fibrin-based provisional matrix by the plasminogen/plasmin system is an important part of the reparative response. Mice lacking plasminogen exhibited markedly attenuated recruitment of inflammatory leukocytes in the infarct and impaired granulation tissue formation (61). Lysis of the fibrin-based matrix is followed by secretion of cellular fibronectin by fibroblasts and macrophages (62, 63) and by deposition of hyaluronan and versican, forming a network of cell-derived provisional matrix that is later enriched with a wide range of matricellular macromolecules (12). During the proliferative phase of healing, the highly dynamic matrix becomes a regulatory center that transduces essential signals to activate reparative fibroblasts and vascular cells.
Components of the provisional matrix regulate fibroblast activation. Repair of the infarcted heart is dependent on recruiting and activating resident fibroblast populations (64) to acquire a myofibroblast phenotype that expresses contractile proteins such as α-smooth muscle actin (α-SMA) and secretes large amounts of collagens. Myofibroblast transdifferentiation requires cooperation between soluble growth factors, such as TGF-β1, and components of the provisional matrix. In vitro, the ED-A domain splice variant of fibronectin is critical for TGF-β1–mediated α-SMA upregulation (65). In vivo, ED-A fibronectin loss attenuates myofibroblast transdifferentiation in healing myocardial infarction (66). The specific interactions between the ED-A segment and the TGF-β–signaling cascade remain unknown. Hyaluronan and versican have also been implicated in myofibroblast conversion. In vitro, pericellular hyaluronan was required to maintain a myofibroblast phenotype in TGF-β–stimulated cells (67). In vivo, loss of CD44, the main receptor for haluronan, impaired collagen synthesis in infarct fibroblasts (40). Versican loss in dermal fibroblasts attenuated myofibroblast conversion (68). Although versican is upregulated in healing myocardial infarcts (69), its in vivo role in transdifferentiation of injury-site cardiac myofibroblasts has not been directly documented.
Induction of matricellular proteins. During the proliferative phase of infarct healing, the cardiac ECM is enriched through the deposition of a wide range of structurally diverse matricellular proteins that do not serve a direct structural role, but act contextually by regulating cytokine and growth factor responses and modulating cell phenotype and function (70, 71). The family includes the thrombospondins TSP-1, -2, and -4, tenascin-C and -X, secreted protein, acidic and cysteine-rich (SPARC), osteopontin, periostin, and members of the CCN family (72). Several other proteins (including members of the galectin and syndecan family, fibulins, osteoglycin, and other small leucine-rich proteoglycans) have been found to exert matricellular actions as part of their broader spectrum of functional properties. Most members of the matricellular family show low expression in the normal myocardium, but are markedly upregulated following myocardial injury. In healing infarctions, angiotensin and growth factors stimulate de novo synthesis and secretion of matricellular proteins in fibroblasts or immune or vascular cells (39, 73, 74). Once secreted into the interstitium, matricellular macromolecules bind to the structural matrix and transduce signaling cascades through ligation of cell surface receptors or contribute to activation of cytokines, growth factors, and proteases in the pericellular space. An overview of the pattern of regulation, function, targets, and mechanisms of action of the matricellular proteins discussed below is given in Table 1.
Matricellular proteins in myocardial infarction
Several prototypical members of the matricellular family are markedly upregulated following myocardial infarction and protect the myocardium from adverse remodeling (75–78). Localized induction of TSP-1 in the infarct border zone may form a barrier that prevents expansion of inflammation in viable myocardial areas through local activation of antiinflammatory signals (75). Osteopontin may protect from left ventricular dilation by promoting matrix deposition in the infarcted region (79). SPARC has been shown to protect from cardiac rupture and postinfarction heart failure by contributing to collagen maturation through activation of growth factor signaling (80). Periostin serves as a crucial regulator of fibroblast recruitment and activity (81) and prevents cardiac rupture (81, 82), promoting formation of an organized collagen-based scar.
Although each matricellular protein has a unique functional profile, several unifying themes have emerged regarding their actions in the infarcted heart. First, the strikingly selective localization of prototypical members of the family in the infarct border zone and their regulatory effects on the activity of soluble mediators highlight their role in spatial regulation of cellular responses. Secreted growth factors and cytokines can diffuse beyond the infarct zone; the requirement for matricellular proteins in activating growth factor–mediated responses may serve to localize inflammatory and fibrotic responses within areas of injury. Second, transient expression of matricellular proteins during the proliferative phase of healing ensures temporal regulation of growth factor responses. Clearance of matricellular proteins from the infarcted area may serve as an important STOP signal, preventing uncontrolled fibrosis following injury. In vitro studies have demonstrated that alternatively activated macrophages internalize SPARC through the scavenger receptor stabilin 1 (83). However, the potential role of immune cell subsets in endocytosis and degradation of matricellular proteins in vivo has not been tested. Third, repair of the infarcted myocardium is dependent on a highly dynamic microenvironment that promotes cellular plasticity. In response to microenvironmental cues, interstitial cells exhibit phenotypic changes (84–86), leading to transitions from inflammatory to reparative phenotypes (87). Through their transient induction and incorporation into the matrix, matricellular proteins may play a critical role in regulating cell differentiation, contributing to the cellular plasticity observed in healing tissues through direct actions and via modulation of growth factor–mediated pathways.
Scar maturation is associated with ECM crosslinking in the infarct zone and with a marked reduction in myofibroblast density (88). Descriptive studies have suggested that apoptosis may be involved in elimination of granulation tissue cells from the infarct (89, 90); however, the mechanisms responsible for cell-specific activation of a proapoptotic program in the late phase of infarct healing have not been investigated. Acquisition of a quiescent phenotype may precede apoptosis of infarct myofibroblasts. Formation of a mature crosslinked matrix and clearance of matricellular proteins may play an important role in regulating fibroblast deactivation in the healing infarct (91–93). It is tempting to hypothesize that endogenous mechanisms that restrain matricellular actions protect the infarcted heart from progressive fibrosis, depriving fibroblasts of the prolonged actions of growth factor–mediated signals. Vascular cells may also respond to the mature ECM environment. During scar maturation, infarct microvessels acquire a coat of mural cells through activation of PDGFR-β signaling (88, 94); uncoated vessels regress. ECM proteins have been implicated in modulation of endothelial-pericyte interactions in vitro and in vivo (95, 96), but whether such effects play a role in maturation of infarct microvessels remains unknown.
It should be emphasized that in the presence of a large infarction with significant hemodynamic consequences, viable noninfarcted myocardium also exhibits slowly progressive interstitial fibrosis related to the pathophysiologic effects of pressure and volume loads. Inflammation and fibrosis are suppressed in the healing infarct, leading to formation of a mature collagen-based scar, but in the viable noninfarcted zone, increased wall stress may locally activate macrophages and fibroblasts, triggering chronic progressive expansion of the cardiac interstitial matrix (97, 98).
Pressure and volume overload are critically implicated in the pathogenesis of heart failure in a wide variety of cardiac conditions. Left ventricular pressure overload is the critical pathophysiologic companion of the cardiomyopathy induced by systemic hypertension and aortic stenosis. On the other hand, valvular regurgitant lesions (such as aortic and mitral insufficiency) cause cardiac remodeling and heart failure by subjecting the heart to volume overload. Moreover, both pressure and volume loads contribute to the pathophysiology of postinfarction remodeling. Pressure and volume overload have distinct effects on the cardiac ECM that may account for their consequences on ventricular geometry and function.
ECM in the pressure-overloaded myocardium. In both experimental models and in human patients, cardiac pressure overload causes early hypertrophic remodeling and diastolic dysfunction, followed by decompensation, chamber dilation, and development of systolic heart failure. Pressure overload is associated with profound and dynamic changes in the composition of the ECM; these changes regulate geometry and function, not only by affecting the mechanical properties of the ventricle, but also by modulating cellular responses. In animal models, activation of cardiac fibroblasts is one of the earliest effects of pressure overload in the myocardium, ultimately leading to deposition of collagenous matrix and expansion of the interstitium (99–101). In human patients, hypertensive heart disease is associated with development of interstitial and periarteriolar fibrosis even in the absence of significant coronary atherosclerosis (102).
Fibrotic changes that develop in the pressure-overloaded myocardium may involve activation of cardiomyocytes, fibroblasts, and immune and vascular cells. Mechanical stress due to pressure overload activates the renin-angiotensin-aldosterone system (RAAS), triggering inflammatory signaling and leading to downstream stimulation of TGF-β cascades. Neurohumoral mediators, cytokines, and growth factors directly stimulate a fibrogenic program, triggering myofibroblast conversion and stimulating synthesis of large amounts of structural matrix proteins (103–106). Stress-induced fibroblast activation in the pressure-overloaded myocardium may also be indirect, at least in part, requiring stimulation of fibrogenic cascades in cardiomyocytes and immune cells. Mechanical stretch has been suggested as triggering purinergic signaling in cardiomyocytes, leading to release of fibrogenic growth factors (107). Moreover, T lymphocytes and macrophages have been implicated in activation of resident cardiac fibroblasts following pressure overload (108, 109).
Even in the absence of cardiomyocyte necrosis, mechanically activated myofibroblasts and immune cells secrete specialized matrix proteins (such as fibronectin) and enrich the interstitial matrix with a wide range of matricellular macromolecules (Figure 3 and refs. 110, 111). Fibronectin deposition in the pressure-overloaded heart may be involved in myofibroblast transdifferentiation and has been implicated as an important mediator in cardiomyocyte hypertrophy (112), possibly through activation of growth factor signaling. Deposition of matricellular proteins in the pressure-overloaded heart generates a highly dynamic matrix microenvironment and modulates fibrogenic and hypertrophic responses. Table 2 provides an overview of the regulation, functional role, and mechanisms of action of the matricellular proteins in the pressure-overloaded myocardium.
Matricellular proteins regulate cellular responses in the pressure-overloaded myocardium. In the pressure-overloaded heart, mechanical stress activates neurohumoral pathways and induces synthesis and release of matricellular macromolecules, including TSP1, -2, and -4, tenascin-C, OPN, SPARC, and periostin. Matricellular proteins have been implicated in regulation of matrix assembly, in transduction of mechanosensitive signaling, and in the pathogenesis of fibrosis and cardiac hypertrophy, and may also modulate survival of cardiomyocytes under conditions of stress. The effects of the matricellular proteins are exerted through direct activation of cell surface receptors or through modulation of growth factor– and protease-mediated responses.
Matricellular proteins in the pressure-overloaded myocardium
ECM in cardiac volume overload. Volume overload is associated with a distinct profile of changes in the composition of the ECM that ultimately lead to chamber dilation and contribute to systolic dysfunction. In contrast to the marked accentuation in collagen deposition triggered by a pressure load, volume overload is associated with a reduction in interstitial collagen content due to increased MMP expression (113–115) and augmented autophagic degradation of procollagen in cardiac fibroblasts (116). Pharmacologic inhibition studies suggested that MMP activation is directly implicated in dilative remodeling of the volume-overloaded ventricle (117), but the mechanisms responsible for the distinct cell biological changes and matrix alterations in volume overload remain poorly understood. Bradykinin receptor signaling has been implicated in matrix loss associated with volume overload (118), but the links between specific mechanical stimuli and myocardial cell activation are understudied. The limited data on the matricellular protein profile in volume-overloaded hearts are not accompanied by systematic investigations of the potential role of these proteins. Although marked increases in synthesis of fibronectin and periostin have been reported in experimental volume overload (114, 119), deposition of these fibrogenic matricellular proteins was not associated with increased secretion of structural matrix proteins.
Diabetics exhibit a high incidence of heart failure with preserved ejection fraction, associated with expansion of the cardiac ECM network (120). Fibrotic changes in diabetic hearts are, at least in part, independent of coronary artery disease or hypertension (121), reflecting direct effects of metabolic dysregulation on the ECM. Diabetes, obesity, and metabolic dysfunction are associated with activation of cardiac fibroblasts (122) and are accompanied by deposition of matricellular macromolecules (123) and progressive accumulation of fibrillary collagens in the cardiac interstitium (124, 125). The molecular basis for activation of the so-called diabetic fibroblast remains unknown. The role of hyperglycemia in mediating fibrogenic activation remains poorly defined. Whether stimulation of a fibrogenic program in diabetic fibroblasts requires diabetes-associated activation of fibrogenic signaling in cardiomyocytes, vascular, or immune cells is unclear. Expansion of the cardiac interstitium in diabetes involves activation of several distinct but overlapping pathways, including neurohumoral mediators (such as the RAAS), ROS, inflammatory cytokines and growth factors (such as TGF-β), adipokines, and the advanced glycation endproduct (AGE)/receptor for AGE (RAGE) axis. Moreover, hyperglycemia induces matricellular protein synthesis in several cell types (126). Diabetes-associated induction of matricellular proteins, such as TSP-1, may drive the fate of cardiac interstitial cells toward a fibroblast phenotype promoting fibrotic remodeling.
Matrix-based strategies to preserve structure, geometry, and function. Because of its importance in preserving structural integrity and function of the heart (127) and its crucial involvement in regulation of cellular responses in cardiac injury, repair, and remodeling (12), the cardiac ECM provides unique opportunities for therapeutic interventions in patients with myocardial infarction and heart failure. Several therapeutic approaches with established beneficial effects in patients with myocardial infarction and heart failure, such as ACE inhibition, angiotensin type 1 receptor blockade, β-adrenergic receptor antagonism, and mechanical unloading, may exert some of their protective actions through modulation of ECM deposition and metabolism (128).
Following myocardial infarction, catastrophic mechanical complications, such as cardiac rupture (129), are associated with accentuated matrix degradation or perturbed deposition of new structural matrix (130). These can be treated through application of a patch containing ECM proteins to restore the structural integrity of the ventricle (131). In the remodeling heart, approaches to tightly regulating matrix deposition and crosslinking may protect from adverse remodeling and development of heart failure. A large body of experimental evidence suggests that excessive accumulation of crosslinked structural matrix proteins increases myocardial stiffness and promotes diastolic dysfunction; in contrast, overactive matrix-degrading pathways may promote dilative remodeling, causing systolic dysfunction. In patients with myocardial infarction, therapeutic interventions directly targeting ECM metabolism through MMP inhibition have produced mixed results. Administration of a selective oral MMP inhibitor in patients with STEMI and reduced ejection fraction showed no significant protection from adverse remodeling (132), despite significant antiremodeling effects in animal models. In contrast, early nonselective MMP inhibition with doxycycline attenuated progression to dilative remodeling in patients with STEMI and left ventricular dysfunction (133). The conflicting findings may reflect the pathophysiological heterogeneity of human myocardial infarction; successful implementation of matrix modulation strategies may require development of biomarkers or imaging approaches to identify patients with specific alterations in matrix metabolism (134). Moreover, interpretation of the effects of therapies targeting MMPs are complicated by their wide range of actions beyond matrix metabolism involving processing and modulation of bioactive cytokines and growth factors.
Matrix-based interventions to modulate cellular cardiac repair responses. Specialized matrix proteins and matricellular macromolecules critically modulate the cellular responses in the infarcted and remodeling heart and may hold the key for development of new effective strategies to optimize repair and to reduce adverse remodeling following cardiac injury. Animal model studies have suggested that several members of the matricellular family protect the infarcted heart from adverse remodeling (12). Therapeutic approaches based on matricellular proteins are particularly attractive because of the capacity of matricellular macromolecules to modulate growth factor and cytokine signaling, thus localizing therapeutic effects in the area of interest. Unfortunately, the daunting complexity of the biology of matricellular proteins hampers therapeutic implementation. Matricellular proteins have multiple functional domains and act contextually depending on microenvironmental factors, such as the local composition of the matrix and the profile of cytokine and growth factor expression. Distinct actions of matricellular protein fragments further complicate therapeutic implementation. Identification of the functional domains responsible for specific protective or detrimental matricellular actions is needed in order to design peptide-based strategies that simulate these effects (12, 135).
Targeting the ECM to promote cardiac regeneration. In contrast with fish and amphibians, adult mammals have very limited capacity for myocardial regeneration (136), which is overwhelmed by the massive sudden loss of cardiomyocytes following infarction. Over the last 15 years, a wide range of cell therapy approaches has been tested in attempts to regenerate the injured human myocardium, with little success (137–139). Although beneficial actions have been reported with several different types of cell therapy, in many cases, protection of the infarcted myocardium was attributed to paracrine effects and to the modulation of inflammatory and fibrogenic signals rather than to activation of a regenerative program.
Several lines of evidence suggest that modulation of the ECM may be a crucial component of a regenerative response. First, in vitro, the composition of the ECM has a profound effect in regulation of cell cycle entry in cardiomyocyte progenitors and in neonatal cardiac myocytes (140, 141). Compliant matrices containing elastin promote dedifferentiation, proliferation, and clonal expansion of rat and mouse neonatal cardiomyocytes (140). Second, in fish and amphibians, myocardial regenerative responses seem to be dependent on deposition of a specialized ECM (142). A recent study reported that intramyocardial administration of ECM from healing zebrafish hearts may stimulate regeneration in mouse infarcts (143). Loss-of-function approaches suggested that fibronectin deposition may be critical for regeneration of the zebrafish heart (144). In newts, cardiac regeneration following injury was preceded by formation of a matrix network comprising tenascin-C, fibronectin, and hyaluronan. This specialized matrix network may serve as a path for progenitor cells as well as play an active role in activation of a regenerative program (145). Considering that, much like in fish and amphibians, myocardial infarction in mammals also induces a marked upregulation of tenascin-C and fibronectin without stimulating remuscularization, it is unlikely that matrix-dependent actions are sufficient to activate a regenerative program. Myocardial regeneration likely requires not only a “regenerative” matrix profile, but also local secretion of a yet-undefined combination of cytokines and growth factors, and activation of pathways that enhance plasticity of progenitor cell populations (146). Third, in several cell therapy studies in mammalian models of cardiac injury, application of matrix-based patches containing progenitor cells showed enhanced effectiveness (147, 148). It has been suggested that application of matrix patches that recapitulate the regenerative environment of the embryonic myocardium may increase remuscularization following injury (149). Whether such effects may be due to direct actions of specific matrix proteins on cardiac progenitors or reflect matrix-dependent activation of other cell types (such as immune or vascular cells) remains unknown. Fourth, some experimental studies in mammals have suggested that matricellular macromolecules may induce proliferation of differentiated cardiomyocytes. Kühn and coworkers showed that recombinant periostin administered as an epicardial Gelfoam patch following infarction improved cardiac function and attenuated cardiac remodeling, triggering cell cycle reentry in differentiated cardiomyocytes in an integrin-dependent manner (150). Unfortunately, genetic manipulation of periostin expression in mice did not support the proposed proliferative actions of periostin on cardiomyocytes (151). Whether modulation of the matricellular protein profile following myocardial injury could facilitate activation of a regenerative program in adult infarcted hearts remains unknown.
A growing body of experimental work attempts to exploit technological advances in perfusion-decellularization strategies (152) to generate scaffolds comprising human cardiac ECM that may serve as tools for manufacture of cardiac grafts (153, 154). The acellular matrix obtained through decellularization could subsequently be used for recellularization with cardiomyocytes derived from induced pluripotent stem cells (iPSCs) in order to generate myocardial-like structures. Early studies have generated tissue constructs with definitive sarcomeric structure that exhibit contractile function and electrical conduction (153). Clearly, the current technology has significant limitations, and major advances are needed in order to pursue clinical translation. Complete reendothelialization is necessary to prevent activation of the coagulation system, generation of functional valvular structures is critical for ventricular function, and a conduction system is needed for transmission of electrical activity. Despite these problems, such matrix-driven strategies may represent the first step toward the generation of functional human cardiac grafts.
All myocardial cells are enmeshed within a dynamic network of ECM that not only serves a structural role and facilitates mechanical force transmission, but also regulates cell phenotype and function. Following cardiac injury, changes in composition of the cardiac ECM critically regulate inflammatory, reparative, fibrotic, and regenerative responses. Over the last two decades, understanding of the biology of the cardiac matrix has expanded well beyond the early concepts focusing on the role of matrix proteins in cardiac mechanics. We now view the matrix as a dynamic entity that responds to injury by undergoing dramatic transformations. Release of bioactive fragments and incorporation of matricellular proteins expands the functional repertoire of the matrix and drives repair by transducing key signals to many different cell types. Expansion of our knowledge on the structure, proteomic profile, and functional properties of matrix constituents will enrich our understanding of the pathobiology of heart disease, suggesting new therapeutic opportunities.
NGF’s laboratory is supported by NIH grants R01 HL76246 and R01 HL85440 and by grants PR151134 and PR151029 from the Department of Defense Congressionally Directed Medical Research Programs (CDMRP).
Conflict of interest: The author has declared that no conflict of interest exists.
Reference information:J Clin Invest. 2017;127(5):1600–1612.